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Summary Two aspects of the aerobic metabolism of nitroimidazole markers for hypoxia were investigated.
Several normal murine tissues which are likely to be well oxygenated bind misonidazole at rates comparable to
those of hypoxic regions in tumours. The possibility that this aerobic activation occurs via an oxygen
independent process such as an initial two electron reduction was studied. Binding to the oesophageal mucosa
of mice which occurred under hypoxia in vitro was inhibited by at least 95% in the presence of 10% oxygen.
Dicoumarol, an inhibitor of DT-diaphorase, was shown to cause only small reductions in misonidazole
binding to oesophageal epithelium and smooth muscle in vitro and to EMT6 tumours, liver, oesophageal and
tracheal epithelium, parotid gland and smooth muscle in vivo. Thus an oxygen-insensitive process is not a
major cause of the high binding rate in oesophageal mucosa, and may not contribute significantly to the
observed binding in other normal tissues. It has been suggested that metabolism of nitroimidazoles by aerobic
cells in tumours might be sufficient to minimise access of these compounds to hypoxic regions, particularly at
the micromolar concentrations currently in use clinically. The uptake of '251-iodoazomycin arabinoside by
RIF-1 and EMT6 tumours was found to be directly proportional to injected dose over concentrations between
0.5 and 501M. Labelling of hypoxic regions in EMT6 tumours by high specific activity 3H-misonidazole at
1 JLM was found to be similar to that obtained at 50;LM.
Non-invasive techniques for monitoring tumour hypoxia
would be valuable prior to radiotherapy in order to under-
stand the natural history of tumour hypoxia, and to identify
individuals for whom standard radiotherapy is likely to be
inadequate so that they may be selected for trials of adjunc-
tive therapies such as perfluorochemical emulsions (Teicher &
Rose, 1984; Guichard, 1991), hypoxic cell cytotoxins (Brown
& Lemmon, 1991), radiosensitiser drugs (Coleman et al.,
1984; Overgaard et al., 1991; Wasserman et al., 1991), and
modulators of tumour perfusion such as nicotinamide (Chap-
lin et al., 1990; Horsman et al., 1990). It was proposed that
2-nitroimidazole drugs could find use as radiopharma-
ceuticals for the diagnosis of tumour hypoxia (Chapman,
1979; Chapman et al., 1981; Urtasun et al., 1986). In hypoxic
tissues bioreduction of 2-nitroimidazoles occurs, forming one
or more reactive metabolites which bind to macromolecules.
Identification of these adducts in vivo has been performed
using positron emission tomography (Rasey et al., 1989),
magnetic resonance spectroscopy (Raleigh et al., 1986), and
single photon emission computed tomography (Parliament et
al., 1992). The exact nature of the reactive metabolites which
form these adducts, and the enzymes responsible for such
nitroreduction, remain to be identified with certainty (Rauth,
1984; Franko, 1986).
Garrecht and Chapman (1983) noted the presence of
significant '4C-misonidazole binding to murine liver, nasal
and oral mucosa, as well as to implanted EMT6 tumours
growing in BALB/c mice. Detailed studies using both scintil-
lation counting and autoradiography have shown significant
retention of misonidazole in many different murine tissues,
including oesophagus, airway epithelium, liver, foot pad,
eyelid (meibomian gland), sebaceous glands, stomach, and
parotid gland (Akel et al., 1986, Cobb et al., 1989, 1990a, b,
c; MacManus et al., 1989). It could be argued that at least
one of these tissues, liver, contains hypoxic cells (Van Os-
Corby & Chapman, 1986, 1987; Maxwell et al., 1989; Mac-
Manus et al., 1989). However, this is unlikely to be the case
for all of these tissues, particularly the airway epithelium
(Cobb et al., 1990a). At least two potential mechanisms may
lead to the observed binding of 2-nitroimidazoles in normally
oxygenated tissues:
1. Nitroreductase activity may be sufficiently elevated in
these tissues to cause an elevated rate of marker bin-
ding, despite competition from oxygen.
2. Nitroreduction might occur due to an enzyme such as
DT-diaphorase, which is a quinone reductase known to
be an obligate 2-electron reductase (Cobb et al., 1989,
1990a).
It is conceivable that if misonidazole were a substrate for
such an enzyme, the production of reactive metabolites could
occur independently of the oxygen concentration. We investi-
gated the latter possibility in two ways. Portions of
esophagus were labelled with 3H-misonidazole in vitro under
conditions which produced an oxygen gradient along the
mucosa, to determine whether the elevated binding rate in
this tissue is oxygen sensitive. Second, the potent DT-
diaphorase inhibitor, dicoumarol (Ernster, 1967) was used to
investigate any possible inhibitory effect on the binding of
3H-misonidazole to oesophageal tissues in vitro and to EMT6
tumour cells and several normal murine tissues in vivo.
Another unresolved question concerning the aerobic
metabolism of nitroimidazoles is relevant to the micro-
distribution of these compounds in vivo. The concentration of
drug available for binding to hypoxic cells should depend on
the rate of supply of the drug by the vasculature and the rate
of metabolism of the drug by the intervening aerobic tumour
cells. It is theoretically possible that at very low drug concen-
trations, as would be used for hypoxic marker imaging in
patients, there might exist sufficient consumption of available
drug to leave some hypoxic regions in the tumour essentially
untouched by the drug (Koch, 1990). In practical terms, we
were concerned that at low plasma drug concentrations the
amount of drug binding would underestimate the hypoxic
fraction of the tumours. Thus we quantified drug binding to
EMT6 and RIF-1 tumours over a 100-fold difference in drug
concentration using a misonidazole analogue, 1251-iodo-
azomycin arabinoside (IAZA) (Mannan et al., 1991). In addi-
tion, we obtained autoradiograms of EMT6 tumours labelled
at an extremely low concentration of 3H-misonidazole by
using a formulation with a high specific activity.
Methods and materials
Portions of mouse esophagus were labelled in vitro with
3H-misonidazole in glass petri dishes at defined oxygen levels
in aluminium chambers, using established procedures
Correspondence: A.J. Franko, Radiobiology Program, Cross Cancer In-
stitute, 11560 University Avenue, Edmonton, Alberta, Canada, T6G 1Z2.
Received 29 April 1992; and in revised form 3 August 1992.
'." Macmillan Press Ltd., 1992 Br. J. Cancer (1992), 66, 1103-11081104 M.B. PARLIAMENT et al.
(Franko et al., 1987). The drug was synthesized by Dr J.A.
Raleigh using a published procedure (Born & Smith, 1983)
which yielded a specific activity of 370 tCi mg-'. Sections of
oesophagus 1-2 mm in length from three female BALB/c
mice were placed in cold Waymouth's medium with 10%
fetal calf serum (Gibco) containing 5011M 3H-misonidazole
and, in half the dishes, 50 JiM dicoumarol. The desired
oxygen levels were achieved by partially evacuating the
chambers and replacing the air with 95% N2-5% CO2. The
chambers were held in an ice-water bath to minimize
misonidazole metabolism during degassing. For severe
hypoxia, eight gas exchanges in 1 h were used to give a final
oxygen level below 5 ppm in the gas phase (Koch et al.,
1984). The chambers were placed on a reciprocating table in
an environmental chamber at 37°C for 3.5 h. The medium
warmed to 37°C in 30 min. The tissue fragments were fixed in
10% buffered formalin for 1 day at 4°C and 1 week at 21°C,
then embedded in wax and sectioned at 5,m. Slides were
dipped in NTB2 emulsion (Kodak) diluted 1:1 with distilled
water and exposed for times determined by inspection of test
slides developed after several times of exposure.
Female BALB/c mice 10 months of age (University of
Alberta Health Sciences Laboratory Animal Services) bearing
EMT6/Ed tumours were labelled with 3H-misonidazole. The
tumours were initiated on both flanks by subcutaneous injec-
tions of 2 x 105 cells from late exponential phase tissue cul-
ture flasks 10 days prior to labelling. Three intraperitoneal
injections of 3H-misonidazole, each chosen to yield a whole
body concentration of 50 JiM, were given at 1 hour intervals.
Half of the mice received dicoumarol both in the drinking
water at a concentration of 180 mg 1 for 24 h prior to
labelling, and via intraperitoneal injections of 34 mg kg-1
dicoumarol 24 and 2 h prior to 3H-misonidazole and concur-
rently with the second injection of 3H-misonidazole (Keyes et
al., 1985). One hour after the last injection, tumours, trachea,
oesophagus and portions of parotid glands and liver were
excised and processed as described above.
Grains were scored using a grid with 10 Lm squares. The
background grain density was determined in several ran-
domly chosen areas in the vicinity of the tissues for each
slide. At least 100 background grains were scored and the
resulting grain density was subtracted from the grain density
over the tissue.
To simulate labelling of humans with very low concentra-
tions of nitroimidazole hypoxia markers, female BALB/c
mice with EMT6 tumours were given six intraperitoneal
injections of 3H-misonidazole at 1 h intervals, each equivalent
to a whole body concentration of 1 JiM. The tumours were
excised 1 h after the last injection and processed as above. To
obtain adequate autoradiograms, 3H-misonidazole with a
specific activity of 15,600 JiCi mg-' was synthesised by Dr P.
Kumar (Born & Smith, 1983).
The concentration dependence of tumour uptake of a
nitroimidazole was studied in EMT6 tumours in female
BALB/c mice and RIF-1 tumours in female C3H/He mice
(Jackson). Tumours were initiated as above. The RIF-1
tumour line was obtained from Stanford University and
maintained as recommended (Twentyman et al., 1980). Cold
IAZA was labelled with '25I by Dr R. Mannan, using the
melt method of exchange in pivalic acid (Mannan et al.,
1991). For the EMT6/BALB/c system, 'l25-IAZA had a
specific activity of 7,000 jiCi mg-'. The drug was injected
intraperitoneally in 0.2 ml sterile saline in doses of 0.18, 1.8
and 18 mg kg-', which were chosen to give approximate
maximum whole body drug concentrations of 0.5, 5.0 and
50 AM. In the case of the RIF-1/C3H/He system, 251I-IAZA
had a specific activity of 2,300 JiCi mg-' and the same quan-
tities of drug were used. The tumours were excised 24 h later,
weighed and 1251 activity determined using a Beckman 8000
gamma scintillation counter (Beckman Instruments Canada
Inc., Mississauga, Ontario). Concentrations of adducts in the
tumours were calculated from the specific activity, assuming
that all non-bound metabolites of the parent drug had been
cleared (Mannan et al., 1991).
Results
Fragments of oesophagus labelled in vitro in nitrogen showed
substantial differences in misonidazole binding between
mucosa and smooth muscle and among different layers of
mucosal cells (Table I). Ten per cent oxygen inhibited bind-
ing to the outermost muscle bundles by approximately a
factor of six, and dicoumarol may have stimulated binding
slightly. Visual inspection of the autoradiograms indicated
that 10% oxygen substantially inhibited binding to the
mucosal cells exposed to the medium at the cut edge, as
shown in Figure 1. A direct test for negative chemography
using parallel slides fogged by exposure to light indicated
that this was not the cause of the reduction in grains over the
cut edge of the oesophagus. During incubation the muscle
contracted and often partially extruded the mucosa on one
end of the fragment and covered it on the other. During cold
fixation the muscle relaxed partially, making it difficult to be
certain of the relationship of the cut end of the mucosa to
the medium.
Grain densities scored over mucosal cells as a function of
distance from the cut edge are shown in Figure 2 for two
regions in which the edges of the muscle and mucosa
appeared to have been undistorted. All grains over all layers
of mucosa were averaged to obtain the largest number of
grains possible at the cut edge. It appears that 10% oxygen
inhibits binding by at least a factor of 20 relative to the
binding achieved deeper in the tissue fragment, where oxygen
must diffuse through the overlying muscle. In fragments
labelled in nitrogen the grain density over the mucosal cells
did not vary with distance from the cut edge (data not
shown). An inhibitory effect of dicoumarol was apparent on
binding to the more heavily labelled mucosal cells and to
smooth muscle (Table I). Insufficient apparently undistorted
regions were found to assess statistically the effect of
dicoumarol on binding at the cut edge.
The grain densities observed in autoradiograms of sections
of several normal murine tissues and EMT6 tumours after
Table I Effect of dicoumarol on 3H-misonidazole binding to fragments of oesophagus in vitro
Gas phase Number of Grains per 100 tLM2
Oxygen level Exposure regions
Cell type (%) (weeks) scored Control Dicoumarol
Mucosa
Basal cells <0.0005 4 30 8.9 + 3.1* 8.0 ± 1.9
Central cells <0.0005 4 30 21.4 5.5 14.0 2.4a
Outermost cells <0.0005 4 30 29.3 ± 6.1 18.1 3.5b
Smooth muscle <0.0005 26 100 58 ± 5.8 33 ± 7.5b
(outermost fibres) 10 26 15** 10.0 0.9 13.7 2.3b
*95% confidence limits.
**In this case, 100 grains were counted for each region scored and divided by the number of
10 m x 10 Lm squares. All other regions were single squares.
aStatistically significant, P<0.05.
bStatistically significant, P<0.01.AEROBIC BINDING OF NITROIMIDAZOLES 1105
Figure 1 Autoradiogram of longitudinal section of esophagus after labelling in vitro with 50gM 3H-misonidazole at 10% oxygen. The exposure time was six months. The cut edge of the oesophageal fragment is on the left, and the lumen of the oesophagus is at
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Figure 2 Grain density over oesophageal epithelial cells as a function of distance from the cut edge for two different oesophageal fragments labelled as in Figure 1. Exposure time of the emulsion was four weeks.
labelling in vivo with 3H-misonidazole are shown in Table II.
A wide range of rates of accumulation of adducts is evident
among different normal tissues and between peripheral
regions of EMT6 tumours and areas adjacent to necrosis.
The presence of dicoumarol during labelling appears to have
had a minor inhibitory effect on the rate of binding of
misonidazole in liver, tracheal epithelium, parotid gland and
hypoxic regions of EMT6 tumours, while little effect is ap-
parent in oesophageal mucosa.
The ability of extremely low concentrations of nit-
roimidazoles to reach tumours after i.p. injection and to
diffuse through aerobic tumour tissue to label hypoxic1106 M.B. PARLIAMENT et al.
Table II Effect of dicoumarol on 3H-misonidazole binding in vivo
Autoradiogram Number of Grains per 1OOlm2
exposure regions
Tissue (weeks) scored Control Dicoumarol
EMT6 tumours
Peripheral areas 10 15* 1.9 0.5** 2.3 0.24
Adjacent to necrosis 6 180 17.2 0.9 14.9 0.9a
Esophageal mucosa
Basal cells 10 30 15.0 2.7 15.3 2.5
Central cells 10 30 29.7 3.2 31.1 ± 2.3
Outermost cells 10 30 43.6 3.7 48.1 ±4.2
Liver 10 30 11.8± 1.3 8.5 1.0a
Parotid gland
Serous cells 17 200 5.5 0.4 4.0 0.35a
Duct cells 17 200 8.9 0.5 6.3 0.5a
Tracheal epithelium 25 20* 29.9± 3.7 16.9 ± 1.7a
*In these cases, 100 grains were counted for each region and divided by the number of
10 Lm x 10 Lm squares scored. All other regions were single squares.
**95% confidence limits.
aHighly significant (P<<0.01) by t-test.
regions was assessed in two ways. Uptake of '25I-IAZA by
EMT6 and RIF-l tumours was compared for a 100-fold
range ofdose (Figure 3). The concentration of IAZA adducts
was found to be directly proportional to the administered
'25I-IAZA dose for both tumours. Second, the distribution of
regions of heavy labelling was assessed in EMT6/Ed tumours
after labelling with 3H-misonidazole injected at a whole body
concentration of 1 t4M. The patterns of labelling were found
to be qualitatively similar to those previously reported for
'4C-misonidazole injected at 50-fold greater dose (Chapman
et al., 1981, 1982). In both cases a five to 20-fold difference in
grain density was seen between cells adjacent to and distant
from necrosis, and essentially all areas of necrosis were sur-
rounded by five to 10 layers of heavily labelled cells.
Discussion
The distribution of misonidazole adducts determined using
autoradiography of tissues from control animals labelled in
vivo (Table II) is generally in agreement with earlier observa-
tions (Garrecht & Chapman, 1983; Akel et al., 1986; Cobb et
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Figure 3 Retention of '25l-iodoazomycin arabinoside in EMT6
(circles) and RIF-I (triangles) tumours 24 h after injection. The
injected doses were equivalent to whole body concentrations of
0.5, 5.0 and 50lM.
the earlier work was performed using scintillation counting
as well as autoradiography indicates that the variations seen
in binding were not the result of chemography. The results
generally have been interpreted as indicating that high levels
of binding of misonidazole can occur in well oxygenated
tissues, implicating a major contribution from an oxygen-
insensitive activation of misonidazole in these tissues. The
possibility that all of these tissues are hypoxic, which would
explain the high levels of binding, cannot be excluded on the
basis of studies such as these, although it would seem to be
extremely unlikely in the case of the airway epithelium, as
noted previously (Cobb et al., 1990a).
In the oesophagus a clear difference was apparent in the
density of binding between the basal epithelial cells and the
outermost cells (Table II), as reported previously (Cobb et
al., 1989). The reason for this is unclear, but due to the
relatively short time between the first misonidazole injection
and the excision of the tissue it is unlikely that the differences
in binding to the mucosal layers would be related to cell
turnover, as suggested by Cobb et al. (1989) based on
examination of tissues excised 24 h after misonidazole injec-
tion.
The results in Figures 1 and 2 demonstrate that direct
access of 10% oxygen in vitro to the cells at the cut edge of
the oesophageal mucosa was associated with an inhibition of
binding by at least a factor of 20 compared to the binding
which occurred deeper in the oesphageal fragment, where the
oxygen level must have been reduced through consumption
by the intervening muscle or epithelial cells. While the
oxygen level in the centre of the tissue fragments is unknown,
the fact that the grain density was similar during labelling in
10% oxygen (Figure 2) and in nitrogen (Table I) suggests
that oxygen consumption by the muscle was sufficient to
create severe hypoxia in the mucosa. In this interpretation of
the data, the gradient of grains from the cut edge of the
mucosa inwards represents the oxygen gradient, and thus
reflects a process of inhibition of binding similar to that seen
in other tissues examined in vitro (Franko & Chapman, 1982;
Franko et al., 1987; Van Os-Corby & Chapman, 1987), albeit
at a much higher level. The results clearly implicate an
oxygen-sensitive reductive process as the major pathway
leading to binding ofmisonidazole to the esophageal mucosa,
although the nature of the dependence of binding on oxygen
concentration is not established by the present data.
However, inhibition of binding of nitroimidazoles by
oxygen has been found to be a continuous, smooth function
of oxygen concentration (over the experimentally accessible
range) in all cell lines and tumour and normal tissues
examined in vitro to date (Franko & Chapman, 1982; KochAEROBIC BINDING OF NITROIMIDAZOLES 1107
et al., 1984; Olive et al., 1986; Franko et al., 1987; Van
Os-Corby & Chapman, 1987; Chapman et al., 1989; Koch,
1990). Assuming that this is also the case for the oesophageal
mucosa, it appears likely that the high levels of binding to
this tissue seen in vivo result primarily from a very high level
of oxygen sensitive bioreductive activity for misonidazole. A
contribution from a low oxygen level cannot be ruled out,
but it is unnecessary to invoke this additional mechanism.
MacManus et al. (1989) reported that binding of
misonidazole to murine heart, liver, spleen and kidney was
increased by exposure of the animals to hypobaric hypoxia,
which supports the idea that metabolic activation of
misonidazole is oxygen-sensitive in these tissues. However, of
these tissues only liver falls in the group of normal tissues
which label heavily under normoxic, normobaric conditions
(Cobb et al., 1989). The distribution of adducts within liver is
heterogeneous, with the distribution of binding consistent
with the postulated oxygen gradient across the functional
hepatic subunit (Cobb et al., 1989; MacManus et al., 1989).
Alternatively, it is likely that there is greater reductase
activity close to the central vein (Cobb et al., 1990a) which
might account for the binding distribution, but this would
not readily account for the increase in binding observed when
the animals were labelled at reduced ambient oxygen levels.
A definite inhibitory effect of 30-40% on binding of
misonidazole by dicoumarol was seen in vitro for two of the
three cell layers scored in oesphageal mucosa and in smooth
muscle (Table I). This drug was chosen for additional studies
of the reductive activation of misonidazole because it is an
effective inhibitor of the 2-electron reductase, DT-diaphorase.
Although the extent of inhibition varies with the nature of
the electron acceptor, the reported range of concentrations
required for 50% inhibition of DT-diaphorase activity in
vitro is 0.001-0.1 lM (Ernster, 1967). Thus it is likely that
the dose of dicoumarol used in the present study, approx-
imately 50tM, was effective in inhibiting dicoumarol activity,
which suggests that the role of DT-diaphorase in the bioac-
tivation of misonidazole is relatively small. However, the
dose of dicoumarol was chosen based on its effect on the
cytotoxicity of other bioreductively activated compounds
(Keyes et al., 1985), and it is clear that the bioreductive
capacity of DT-diaphorase varies considerably depending on
the substrate (Workman et al., 1989). Furthermore, at high
concentrations dicoumarol may have effects on other
biochemical pathways (Marshall et al., 1989) which con-
ceivably might affect the activation ofmisonidazole. Thus the
results in Table I support the conclusion that oxygen-
insensitive bioreduction makes at most a small contribution
to misonidazole binding under these conditions, but the mag-
nitude of this contribution cannot be estimated with certainty
from these data.
The effect of dicoumarol on misonidazole binding in vivo
was slightly inhibitory in the liver, airway epithelium, parotid
gland, and in areas adjacent to necrosis in EMT6 tumors
(Table II). No significant effect on binding was noted in
peripheral areas of EMT6 tumours, or in the oesophageal
mucosa in vivo. Since only three animals were used in each
group, it is possible that biological variability obscured a
small inhibitory effect of dicoumarol in the latter tissues. The
grain density over aerobic regions of tumours was too low to
yield reliable comparisons of binding levels differing by less
than 50%. Considerable additional work would be required
to establish the exact levels of inhibition of binding in each
tissue and to resolve some discrepancies between the in vivo
and in vitro results. However, it is clear that the effect of
dicoumarol was in all cases small when compared to the
magnitude of the differences in binding of misonidazole
among the presumably aerobic normal and tumour tissues
shown in Table II. This implies that the major source of
these differences is unlikely to be an initial 2-electron reduc-
tion which can be inhibited by this concentration and
schedule of dicoumarol. However, we cannot rule out the
possibility that inadequate absortion of enteral/
intraperitoneal dicoumarol contributed to a lower plasma
concentration than anticipated. Thus the in vivo results pro-
vide only modest support for the hypothesis that in general
normal tissues which exhibit a high rate of binding of nit-
roimidazoles do so because of elevated nitroreductase levels
rather than because of an oxygen-insensitive activation path-
way or because of local hypoxia. Considerably more work is
required to fully test this hypothesis.
An important implication of the foregoing interpretation is
that tumours derived from tissues which show a high level of
aerobic binding of misonidazole would not be precluded
from assessment of hypoxia using bioreductively activated
hypoxia markers. Such tumours would also show a propor-
tionately higher level of hypoxic binding, so the ability to
discriminate among tumours of the same histological type
with differing hypoxic fractions should be unaffected. This
depends, of course, on the assumption that all tumours of a
given type have similar misonidazole binding characteristics,
as has been found for a series of small cell lung cancers
(Chapman et al., 1989).
The data in Figure 3 demonstrate that delivery of the
misonidazole analogue, IAZA, to EMT6 and RIF-1 tumours
was equally efficient over a concentration range of
0.5-5011M, and the results imply that access of the drug to
hypoxic cells via diffusion through aerobic tumour tissue was
not affected by concentrations in this range. However, une-
quivocal interpretation of the results is made difficult by the
fact that binding ofmisonidazole to hypoxic cells depends on
the square root of misonidazole concentration (Chapman et
al., 1983; Koch et al., 1984). Definitive evidence for the ready
access of drug to hypoxic regions is provided by the
autoradiographic demonstration that the preferential binding
of 3H-misonidazole to cells adjacent to necrosis in EMT6/Ed
tumours was qualitatively similar at injected doses equivalent
to whole body concentrations of one and 50 LM. Thus at
least for tumours such as the EMT6 and RIF-1 which dem-
onstrate relatively low levels of binding to aerobic tissue, the
present data appear to contradict the recent suggestion
(Koch, 1990) that consumption of nitroimidazoles by aerobic
tumour tissue might constitute a significant impediment to
labelling of hypoxic cells at clinically achievable doses.
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